Novartis AG to buy immunology specialist Calypso Biotech BV
Upon closure, the US$425m take-over of the Amsterdam-headquartered Calypso Biotech NV, would give Novartis AG full commercialisation rights to...
Alfasigma SpA signs €170m deal with Galapagos NV
With the transaction that is expected to close in Q1/2024, Alfasigma will strengthen its pipeline, add a new Phase III programme to...
Novo Nordisk to acquire Cardior Pharmaceuticals
The take-over agreement includes Cardior’s lead compound CDR132L, currently in Phase II clinical development for the treatment of heart failure....
Roche jumps ship on AC Immune
In recent trials, both Semorinemab, a monoclonal antibody (mAb) binding all forms of Tau, and Crenezumab, a mAb targeting multiple forms of misfolded...
Finnish Enifer Oy secures €12m grant to scale up
The new factory will have a production capacity of around 3 million kilograms a year – equal to the amount of protein from 30,000 cows but with...
GLP1 agonists: FDA investigates suicide risk
It is rare for the US Food and Drug Administration (FDA) to act more slowly than its European counterpart, the EMA. However, this is the case with...
Alvotech Advances in Biosimilar Market with Successful AVT03 Study
Alvotech SA, a global biotech company from Luxembourg, specialising in biosimilars, reported positive results from a pharmacokinetic study of AVT03,...